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Background: The voriconazole and echinocandin combination has been found to be synergistic in vitro and
in vivo against most Aspergillus fumigatus isolates, both with a WT azole phenotype and an azole-resistant
phenotype. The interaction between isavuconazole and echinocandins is less well studied. This is especially true
for azole-resistant isolates.
Objectives: We investigated the in vitro interaction between isavuconazole and anidulafungin for 30
A. fumigatus isolates including 18 azole-resistant isolates with various isavuconazole resistance phenotypes.
Methods: The isavuconazole/anidulafungin interaction was studied by using an adapted EUCAST-based 2D
(12%8) chequerboard broth microdilution colorimetric assay using XTT. The interaction was analysed by FIC
index (FICi) analysis and Bliss independence (BI) interaction analysis.
Results: Both the FICi analysis and the BI analysis showed synergistic interaction between isavuconazole and
anidulafungin for the majority of WT and azole-resistant isolates. As we did not see significant beneficial effects
of combination therapy in TR46/Y121F/T289A isolates at clinically achievable drug concentrations, it is unlikely
that TR46/Y121F/T289A infections would benefit from isavuconazole and anidulafungin combination therapy.
Conclusions: In regions with high azole resistance rates this combination may benefit patients with WT
disease, azole-resistant invasive aspergillosis and those with mixed azole-susceptible and azole-resistant
infection, but may not be beneficial for aspergillosis due to isolates with high isavuconazole resistance, such as
TR46/Y121F/T289A isolates.
Introduction
It is estimated that worldwide approximately 300 000 people suf-
fer from invasive aspergillosis annually.1 Voriconazole and isavuco-
nazole are currently recommended as first-line agents for the
treatment of patients with invasive aspergillosis.2–4 However, the
emergence of azole resistance in Aspergillus fumigatus greatly
challenges the management of invasive aspergillosis. As resist-
ance selection may take place in the environment, any patient is
at risk and may present with azole-resistant disease.
Environmental resistance is dominated by isolates that harbour a
tandem repeat (TR) in the promoter region of the cyp51A target
gene combined with amino acid alterations, i.e. TR34/L98H and
TR46/Y121F/T289A. Although these mutations alter the activity of
all medical triazoles, TR34 isolates are highly resistant to itracon-
azole, whereas TR46 isolates are highly resistant to voriconazole.
5,6
In regions with endemic resistance levels exceeding 10%, an
international expert panel recommended to move away from
azole first-line therapy and treat with liposomal amphotericin B, or
to use voriconazole combined with an echinocandin.7 The voricon-
azole and echinocandin combination was found to be synergistic
in vitro and in vivo against most A. fumigatus isolates with a WT
azole phenotype.8–19 Importantly, similar beneficial effects of this
combination were also seen in most azole-resistant A. fumigatus
isolates.8–12,18 However, these studies involved isolates with
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voriconazole EUCAST MICs of 0.5–8 mg/L and it remains unclear
whether an azole and echinocandin combination can be benefi-
cially used in isolates with high resistance to voriconazole (MICs
>8 mg/L). There is a risk that in patients with infection due to highly
voriconazole- or isavuconazole-resistant isolates the benefit of
combination therapy is lost and therapy is based on the echino-
candin efficacy, which is suboptimal in (neutropenic) patients with
invasive aspergillosis.20,21
Isavuconazole was shown to be non-inferior to voriconazole for
the treatment of invasive aspergillosis and thus received an A-I
recommendation in most guidelines, similar to that of voricon-
azole.2–4,22 Given the favourable pharmacokinetics and toxicity
profile of isavuconazole, the drug is increasingly used in patients
with invasive aspergillosis. There is currently limited evidence to
support isavuconazole and echinocandin combination therapy. To
the best of our knowledge, only two studies to date have investi-
gated the interaction of isavuconazole with an echinocandin and
only five azole-resistant A. fumigatus isolates (three with
TR34/L98H mutation, one with G54W and one with P216L) were
tested.23,24 Therefore, we investigated the in vitro interaction
between isavuconazole and anidulafungin for 30 A. fumigatus




A total of 30 A. fumigatus isolates were used in the study, of which 18 were
azole-resistant with a known cyp51A mutation [6 isolates with TR34/L98H, 2
with TR46/Y121F/T289A, 3 with G54 (G54R, G54E, G54E), 4 with M220
(M220I, M220K, M220R, M220V), 1 with P216L, 1 with G448S and 1 with
G138C] and 12 phenotypically azole WT isolates.
Antifungal agents and XTT/menadione
Isavuconazole (Sigma–Aldrich, St Louis, MO, USA) and anidulafungin
(Sigma–Aldrich) were dissolved in DMSO at a concentration of 3200 mg/L.
Antifungals were further diluted in RPMI 1640 to obtain the desired concen-
trations (described below) by serial dilutions according to the ISO scheme
for preparing antifungal dilution series.25,26 Final antifungal concentrations
ranged from 0.008 to 8 mg/L for isavuconazole and 0.008 to 0.5 mg/L for
anidulafungin.
XTT (Sigma–Aldrich) was dissolved in sterile saline to produce a concen-
tration of 500 mg/L. Menadione (Sigma–Aldrich) was first diluted in abso-
lute ethanol at a concentration of 10 000 mg/L and was then added to the
XTT solution to produce an XTT/menadione solution of 31.25 lM mena-
dione and 500 mg/L XTT. Fifty microlitres of XTT/menadione solution was
added to the wells after 48 h of incubation, resulting in final concentrations
of 100 mg/L XTT and 6.25lM menadione. The latter concentrations of XTT
and menadione were chosen as these were previously found to be optimal
for caspofungin.27
MIC determination and chequerboard XTT assay
The isavuconazole/anidulafungin interaction was studied by using an
adapted EUCAST-based 2D (12%8) chequerboard broth microdilution
colorimetric assay using XTT, as described previously.28 Four-fold the
final concentration of isavuconazole or anidulafungin was diluted in 2-
fold concentrated medium. Fifty microlitres of both isavuconazole and
anidulafungin concentrations were added to 96-well microtitre plates
to obtain 2-fold final concentrated medium and antifungal
combinations. Prepared microtitre plates were stored at #70C for a
maximum of 4 weeks. Spore suspensions were prepared spectrophoto-
metrically (Spectronic GENESYS 20) in sterile saline supplemented with
0.1% Tween 20 (Sigma–Aldrich) and further diluted in sterile saline to
obtain a dilution of 1%106–4.2%106 conidia. One hundred microlitres of
inoculum was added to the 96-well plates and the plates were incu-
bated at 35–37C. Microtitre plates were then incubated for 48 h. The
activities of isavuconazole and anidulafungin were determined in ac-
cordance with the EUCAST reference methods.25 The anidulafungin
minimal effective concentration (MEC) was read visually after 24 h and
the isavuconazole MIC was read visually after 48 h. After 48 h, 50 lL of
prepared XTT/menadione solution (to produce final concentrations of
6.25 lM menadione and 100 mg/L XTT) was added to the wells and incu-
bated for a further 2 h. Conversion of XTT to formazan was measured as
OD with a microtitre plate reader (Anthos Labtec Instruments HT3
Microtiter Plate Reader) at 450 nm with 630 nm as reference.
Background OD from a similar incubated microtitre plate with added
XTT/menadione solution but without inoculum was subtracted from the
measurements.11,28 Measurements were performed in triplicate.
Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were
used as quality controls.
Interaction models
The interaction was analysed using two interaction models. The first was
the FIC index (FICi) with inhibition endpoints based on XTT metabolism,
where an FICi of0.5 indicates synergism and an FICi of >4.0 indicates an-
tagonism. An FICi between 0.5 and 4 indicates indifferent interaction. Two
different endpoints were used. FIC1 was defined as 90% inhibition of for-
mazan production compared with growth control. This endpoint, based on
inhibition of formazan production, corresponded well to the isavuconazole
visual MIC endpoint. FIC2 was defined as 75% inhibition compared with the
growth control. Offscale MICs were adjusted to the next 2-fold higher or
2-fold lower concentration. FIC1 and FIC2 were calculated for each
replicate individually. When only 2/3 samples were in accordance, the
interaction conclusion of the majority was used for the isolate.
The second model used was the 3D surface interaction model based on
the Bliss independence (BI) theory as previously described.11,29 The
expected growth was calculated based on the BI model using Excel (2010)
and GraphPad Prism (5.03). The expected growth was subtracted from
observed growth for all three replicates and the mean was used as the BI
result. BI results were tested for significance using a t-test. The sum of all
significant BI results was used to calculate Bliss interaction (DE), where a
positive DE indicates synergism and a negative DE indicates antagonism.
The zero surface indicates no interaction.
Results
The interaction between isavuconazole and anidulafungin was
synergistic for the majority of isolates (Table 1). As the MEC end-
point for anidulafungin without isavuconazole, which corre-
sponded to 50% inhibition, was out of range for most isolates,
this endpoint was excluded from the analysis. The FICi could not
be determined for TR46/Y121F/T289A isolates as all defined FIC
endpoints were out of the tested range. For all other isolates
combined, the FIC1 was between 0.27 and 1.02. The geometric
mean (GM) of FIC1 was between 0.5 and 4 when isolates were
analysed in subgroups (WT, isolates with TR34/L98H and isolates
with cyp51A point mutations, respectively). The interaction was
synergistic for 2 isolates and indifferent for 26 isolates using the
FIC1 endpoints. No antagonism was observed. The FIC2 end-
point ranged between 0.002 and 1.02. The FIC2 GMs of sub-
groups (WT, isolates with TR34/L98H and isolates with cyp51A
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point mutations) were <0.5. The interaction was synergistic for
7/12 WT isolates, 6/6 isolates with TR34/L98H and 7/10 isolates
with cyp51A point mutations. No antagonism was observed
(Table 1). TR46/Y121F/T289A isolates were excluded as all FIC
endpoints were offscale and interaction based on FIC analyses
could not be calculated. The results of the FIC analysis were con-
firmed with BI analysis, with a mean DE of 138%, indicating syn-
ergism (Table 1). Five isolates had an antagonistic interaction
according to the BI analysis, while 24 had a synergistic inter-
action (Table S1, available as Supplementary data at JAC
Online). The 3D surface diagram is displayed for the WT isolate
AZN8196 with an isavuconazole MIC of 0.5 mg/L (Figure 1). The
mean DE was higher for WT isolates compared with TR34/L98H
isolates and isolates with cyp51A point mutations, but not sig-
nificantly different. Only minor interaction was seen for TR46/
Y121F/T289A isolates. At the range of concentrations used in
the experiment, no favourable results were observed. The DE
was 0% for one TR46 isolate while only minor antagonistic inter-
action was observed for the other isolate (DE of #19%).
Discussion
We found predominantly synergistic in vitro interaction between
isavuconazole and anidulafungin for most azole-susceptible and
azole-resistant A. fumigatus isolates. Both statistical methods, FIC
analyses and BI analyses were in concordance. However, the FIC
results varied between the FIC endpoints that were defined.
In vitro and in vivo data already support a beneficial interaction
between voriconazole and anidulafungin for invasive aspergil-
losis.8–17,19 Similar results were found for posaconazole or itracon-
azole with an echinocandin.29–33 This study indicates a favourable
effect of combination therapy with isavuconazole and anidulafun-
gin for A. fumigatus for both azole-susceptible and -resistant iso-
lates with isavuconazole MICs between 1 and 8 mg/L.
Importantly, the favourable effects of combination therapy
were not observed in our interaction model for isolates with
TR46/Y121F/T289A mutations having isavuconazole MICs
>8 mg/L. To investigate drug interactions, the range of drug
combinations used in the interaction model should be around
the MIC of the drug. However, the precise isavuconazole MICs
for TR46/Y121F/T289A isolates are not known as the standard
susceptibility testing range is truncated at 8 or 16 mg/L for isa-
vuconazole and the exposure needed to treat isolates with such
high MICs is not achievable in humans. Therefore, we did not ex-
tend the range of isavuconazole drug concentrations tested in
our in vitro model. Thus, we cannot exclude a synergistic inter-
action between isavuconazole and anidulafungin in isavucona-
zole highly resistant A. fumigatus isolates. As we did not see
significant beneficial effects of combination therapy at clinically
achievable drug concentrations, it is unlikely that TR46/Y121F/
T289A infections would benefit from isavuconazole and anidu-
lafungin combination therapy. This implies that when using isa-
vuconazole plus anidulafungin for infections with TR46/Y121F/
T289A, only the efficacy of the echinocandin remains, which
is suboptimal.20,21 Thus, in geographic regions with a high
incidence of TR46/Y121F/T289A or in cases with documented
TR46/Y121F/T289A infection, liposomal amphotericin B alone, or
in combination with an azole, should be considered.
The in vitro results of FIC2 and the BI analysis of this study are
comparable to the in vitro results of the combination of voricon-
azole and anidulafungin that was tested with the same method-












































Figure 1. BI surface diagram for the combination of isavuconazole and anidulafungin for A. fumigatus isolate AZN8196. The 0 surface indicates no
interaction whereas the surface above 0 indicates synergistic interaction. This figure appears in colour in the online version of JAC and in black and
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aspergillosis.10 However, when we used the FIC1 endpoint the
interactions were predominantly indifferent whereas most inter-
actions of voriconazole and anidulafungin remained synergistic at
the FIC1 endpoint. However, the difference in mean FICi was only
small (0.6 for isavuconazole/anidulafungin versus 0.4 for voricon-
azole/anidulafungin), which challenges the clinical significance of
the observed difference.11 Therefore, we anticipate similar benefi-
cial effects of isavuconazole/anidulafungin when used in vivo com-
pared with voriconazole/anidulafungin.
Similar interactions of isavuconazole/anidulafungin were found
in an in vitro study that evaluated the combination of isavucona-
zole and anidulafungin for five azole-resistant A. fumigatus iso-
lates.24 That study also found that the interaction was
predominantly indifferent when complete inhibition was used as
the endpoint (e.g. FIC1 in the current study), while 2/5 isolates
showed synergistic interaction when incomplete inhibition (e.g.
FIC2) was used as the FIC endpoint. This indicates that addition of
anidulafungin does not reduce the MIC of isavuconazole, but does
add to the inhibitory effect at subMIC levels.
Although the combination of voriconazole with anidulafungin
did not result in significantly better efficacy in a randomized control
trial, post hoc analysis indicated that the combination may be bene-
ficial for a subgroup population with Aspergillus galactomannan in-
dices between 0.5 and 1.5.34 Thus, in regions with high azole
resistance rates the combination may benefit patients with WT dis-
ease, azole-resistant invasive aspergillosis and those with mixed
azole-susceptible and azole-resistant infection, but may not be
beneficial for aspergillosis due to isolates with high isavuconazole
resistance such as isolates with TR46/Y121F/T289A. As similar
in vitro interactions were found for isavuconazole and anidulafungin
compared with the voriconazole and anidulafungin combination,
the results of this study indicate that voriconazole can be replaced
by isavuconazole when used in combination with an echinocandin.
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